Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar 31;12(3):647-648.
doi: 10.21037/tlcr-22-897. Epub 2023 Mar 1.

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?

Kuan-Yu Lee  1 , Chen-Xiong Hsu  2   3
Affiliations
Comment

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?

Kuan-Yu Lee et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Adjuvant chemotherapy; adjuvant immunotherapy; completely resected; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-897/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Park CK, Oh HJ, Yoo SS, et al. Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial. Transl Lung Cancer Res 2022;11:1606-18. 10.21037/tlcr-22-183 - DOI - PMC - PubMed
    1. O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23:1274-86. 10.1016/S1470-2045(22)00518-6 - DOI - PubMed
    1. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344-57. 10.1016/S0140-6736(21)02098-5 - DOI - PubMed
    1. Pathak R, Goldberg SB, Canavan M, et al. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncol 2020;6:1741-50. 10.1001/jamaoncol.2020.4232 - DOI - PMC - PubMed